- Pluristem Therapeutics (PSTI) rallies 3.6% premarket.
- The company says its PLX cells "proved to be safe in an animal study assessing maternal and fetal toxicity."
- When administered intramuscularly in pregnant rats, the PLX-PAD cells "did not result in any maternal or fetal toxicity."
- Here's CEO Zami Aberman: "This study, together with the work performed by Dr. Brett Mitchell from Texas A&M College of Medicine,suggesting that our PLX-PAD cells are efficacious in preeclamptic animal models, is an important milestone towards our goal of initiating clinical trials for preeclampsia." (PR)
From other sites
at 4-traders.com (Mar 24, 2015)
Pluristem Therapeutics : Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indicationsat 4-traders.com (Mar 24, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Mar 18, 2013)
at MarketWatch.com (Sep 13, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs